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The health burden of non-alcoholic fatty liver disease (NAFLD) is multifaceted. In addition to 43 
sequelae of end-stage liver disease and hepatocellular carcinoma, the deleterious role of 44 
hepatic steatosis in the development of type 2 diabetes and cardiovascular disease is also 45 
well established.(1,2) NAFLD affects up to one third of the adult population and may 46 
become more prevalent with the escalation of obesity globally. Therefore, there is an urgent 47 
need for effective therapies for not only reducing steatosis and liver injury, but for 48 
improving insulin resistance and the cardiovascular risk associated with NAFLD. 49 
Although there are many promising drug therapies in phase II and III clinical trials, treating a 50 
large proportion of the population with medications for many years will be an expensive 51 
management option at a population level. As there are no pharmacological agents currently 52 
accepted for the long-term treatment of NAFLD, the mainstay of treatment is weight loss via 53 
lifestyle intervention incorporating dietary and structured exercise intervention.(3) Indeed, 54 
weight gain is arguably the strongest determinant of the development of NAFLD (4), and 55 
weight loss is the greatest predictor of reductions in liver fat and aminotransferases.(3) Even 56 
small reductions (3-5% body weight loss) reduce steatosis and associated metabolic 57 
parameters however, larger reductions (≥10%) appear to be required for histologic 58 
improvements of liver injury.(5) Whilst weight loss is effective, it is notoriously difficult to 59 
sustain in the long term.(6) Exercise is routinely recommended for the management of 60 
NAFLD, since the efficacy of exercise per se for the reduction of liver fat is now recognized 61 
(7), and exercise has a multiplicity of benefits beyond weight loss. While questions regarding 62 
the optimal ‘dose’ of exercise therapy for reducing liver fat have been the focus of recent 63 
clinical investigations, consensus as to how effective exercise is over a longer term at a 64 
population level is unclear. Furthermore, how much exercise is required to prevent or 65 
  
reverse NAFLD has remained elusive. This is in part due to the paucity of epidemiological 66 
data to support the findings of smaller clinical trials.  67 
In this issue of the Journal of Hepatology, Sung and colleagues examine the association 68 
between exercise with both incident NAFLD and the resolution of NAFLD in a large cohort of 69 
adults followed over a mean of five years (8). This paper provides the first longitudinal 70 
epidemiological data to support the utility of exercise in both the prevention and treatment 71 
of NAFLD. Within the setting of an occupational health screening program, 169,347 men and 72 
women had repeat measures of liver fat (quantified with ultrasound) and physical activity. 73 
Of the 126,811 adults at baseline without NAFLD, 23% developed NAFLD at follow up and 74 
displayed an adverse cardiovascular risk profile when compared with participants who 75 
remained free from NAFLD. Of the 42,536 individuals with NAFLD at baseline, 34% of cases 76 
resolved. After adjusting for potential confounders, including change in body mass index 77 
(BMI), any level of moderate-vigorous exercise was associated with both a reduced risk of 78 
incident NAFLD and with the resolution of NAFLD. The greatest benefits were observed with 79 
exercise frequency ≥5 days per week, with a 16% reduction in NAFLD incidence and 40% 80 
increase in NAFLD resolution over the follow-up. Higher levels of exercise at baseline and 81 
increasing the frequency of weekly exercise bouts over time were also associated with a 82 
lower risk of incident NAFLD and the resolution of NAFLD.  83 
These data have evident clinical ramifications with the authors concluding that weekly 84 
exercise of moderate-vigorous intensity independently reduces the risk of developing 85 
NAFLD, and improves the resolution of existing NAFLD. Noteworthy limitations were the 86 
diagnosis of NAFLD via ultrasound, which has limited ability to detect smaller changes in 87 
liver steatosis, the lack of dietary data and the assessment of exercise by the Korean version 88 
  
of the International Physical Activity Questionnaire Short Form. This self-report method, 89 
which recalls physical activity behavior over a seven-day period, is prone to self-report bias 90 
and typically leads to an overestimation of physical activity levels. Nevertheless, a dose-91 
response relationship was observed between reported exercise frequency and protection 92 
from incident NAFLD as well as future NAFLD resolution, suggesting a true ‘causal’ 93 
relationship. However, the IPAQ questionnaire assessment is only semi-quantitative and 94 
thus the ability of the study to determine the optimal prescriptive ‘dose’ of exercise 95 
(encompassing the frequency, intensity, duration and type of exercise) is limited.  96 
This information gap is filled in part, by smaller, short-term, randomized controlled trials 97 
(RCT’s) examining the efficacy of exercise for the reduction of liver fat. Multiple studies 98 
examining aerobic exercise, typically comprising 30-60 minutes of moderate to vigorous 99 
exercise on 3-5 days per week, have consistently demonstrated benefits with mean 10-44% 100 
relative reductions in intrahepatic lipid by magnetic resonance spectroscopy.(7) Notably, a 101 
recent RCT demonstrated no difference between low volume high-intensity and high 102 
volume low-intensity aerobic exercise, in reducing hepatic steatosis, suggesting different 103 
combinations of aerobic exercise may be equally beneficial.(9) In addition to reducing liver 104 
fat, these doses of exercise have clear extra-hepatic benefits including improvements in 105 
comorbid insulin resistance, systemic inflammation, dyslipidaemia, hypertension and 106 
endothelial dysfunction.(10) Thus, the well-established protective effect of physical activity 107 
on cardiovascular morbidity and mortality in the general population is likely to be applicable 108 
to patients with NAFLD.(11) Given that cardiovascular disease remains the leading cause of 109 
death in NAFLD patients, encouraging regular exercise should be advocated independently 110 
of its effect on liver disease.   111 
  
 Benefits are also seen with resistance-based exercise, although the evidence for 112 
resistance-based exercise for reducing steatosis is less consistent with large heterogeneity in 113 
the dose of resistance training employed. Whether resistance training is as efficacious in 114 
reducing hepatic fat as aerobic exercise is unclear, with one small RCT demonstrating no 115 
difference between interventions whereas a larger trial over 8 months favoured aerobic 116 
exercise.(12,13) However, resistance training improves insulin sensitivity, muscle strength 117 
and function, which are important given the recently demonstrated association between 118 
sarcopenia and risk of NAFLD.(14) In accordance with clinical recommendations for 119 
resistance exercise in cardiovascular disease risk modification, the current evidence 120 
suggests that resistance training should complement, rather than replace, aerobic exercise 121 
training.(15)  122 
As exercise has been convincingly demonstrated to reduce hepatic steatosis, improve liver 123 
enzymes and ameliorate insulin resistance, it would be anticipated that it might also 124 
improve liver inflammation and injury in patients with NAFLD.  Cross-sectional data from 125 
NAFLD patients undergoing liver biopsy, suggests that individuals who reported engaging in 126 
vigorous-intensity exercise have a lower BMI-adjusted odds for non-alcoholic 127 
steatohepatitis (NASH) and advanced fibrosis.(16) However, there are no clinical trials 128 
examining optimal doses of exercise that reverse liver injury and fibrosis. Moreover, while 129 
lifestyle intervention resulting in >7-10% weight loss has been associated with a reduction in 130 
liver injury and fibrosis (6), there is currently no evidence to suggest that exercise in 131 
isolation without concomitant weight loss can reduce NASH or fibrosis. Thus there is a need 132 
to determine the interaction between exercise and NASH, fibrosis and the associated 133 
metabolic outcomes, as well as the added benefits of exercise atop of weight loss for liver-134 
related outcomes. A major limitation for research in this field is the invasive nature of liver 135 
  
biopsy, which is not palatable for the majority of patients. Thus, future population studies 136 
incorporating non-invasive assessment of fibrosis such as transient elastography or non-137 
invasive markers are eagerly awaited. 138 
The large sample size included in Sung and colleagues work allows for a well-powered 139 
analysis of free-living individuals at a population level, and thus considerably strengthens 140 
the consensus that exercise is effective as a prevention and treatment strategy for NAFLD. 141 
This study also reinforces that NAFLD is a dynamic condition, with one-third of the 42,536 142 
individuals with fatty liver at baseline having resolution after five years. Resolution was 143 
associated with a modest mean reduction in BMI (-0.5 kg/m
2
) and increase in the number of 144 
weekly exercise sessions. Thus, relatively modest weight reduction in conjunction with 145 
increased exercise frequency has the potential to significantly impact on the prevalence of 146 
NAFLD at a population level. While most successful lifestyle interventions will be 147 
multidisciplinary (including dietitians, exercise specialists and psychologists), these findings 148 
highlight that emphasis should be placed on exercise adoption and maintenance in the 149 
primary management of NAFLD. Patients with NAFLD have been shown to understand the 150 
‘benefits of exercise’ however don’t participate due to low confidence and a fear of falling, 151 
highlighting the need for strategies to overcome these barriers.(17) Promising therapies 152 
include high intensity interval training (HIIT) with a recent study employing a modified HIIT 153 
protocol (combined aerobic and resistance exercise) demonstrating significant reductions in 154 
steatosis and improved cardiac function.(18) Pilot studies examining acceleration training 155 
(resistance exercise performed on a vibration platform) and hybrid training (involving the 156 
voluntary and electrical contraction of muscles) demonstrate the potential for innovative 157 
strategies to also improve liver fat in NAFLD.(19,20) 158 
  
While further research will enable clinicians to titrate the dose required for individual 159 
benefit across the spectrum of NAFLD, there is now clear consensus that exercise is a 160 
‘polypill’ for the management of NAFLD; we just need to learn how to get patients to take it 161 
regularly and seriously.  162 
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